A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Durvalumab (Primary)
Indications Advanced breast cancer; Anal cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Kaposi's sarcoma; Lymphoma; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Small cell lung cancer; Solid tumours
Focus Therapeutic Use
Acronyms DURVAST

04 May 2022 Status changed from active, no longer recruiting to completed.
21 Sep 2020 Results of extended follow up analysis presented at the 45th European Society for Medical Oncology Congress
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com